Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
GEA has introduced the ConsiGma FC Flex, a production-scale film coater for tablets, capsules, and pellets. It processes approximately nine-kilogram sub-batches in six-minute cycles and retains the laboratory system’s drum diameter while changing drum depth and nozzle count. Standard containment targets OEB 4, with an optional cleaning upgrade supporting OEB 5–6 applications, according to the supplier.
Piramal announced that its new Lexington microbiology laboratory entered routine GMP use on September 11, with the sterility suite subsequently conditionally approved. The lab expands testing space and adds a Grade A isolator intended to double sterility-testing capacity. It is an early component of an $85 million sterile-injectables expansion; the remaining manufacturing capacity is expected in late 2027.
Hovione plans to install a $35 million ConsiGma CDC Flex line at its East Windsor, New Jersey, campus, with commissioning expected in late 2027. The system will link spray-dried amorphous solid dispersions to tablet production under one quality system. Planned continuous and batch modes span 1 to 200 kilograms per hour, with development possible using 1.5 kilograms.
This study applied multidimensional electron diffraction to cabotegravir nanocrystals within a long-acting injectable formulation. 3D electron diffraction confirmed a structure consistent with the known X-ray model, while imaging and diffraction linked particle shape to crystal structure and revealed dislocations. The results describe nanoscale structural features that may guide formulation work; improved product performance was not demonstrated.
Synthego and Biomay announced a nonexclusive North American marketing and resale collaboration covering CRISPR components and manufacturing services. The offering combines Synthego guide RNA expertise with Biomay’s Cas9, mRNA manufacturing, LNP formulation, and aseptic fill-finish capabilities, including research and cGMP options. This is a commercial supply collaboration rather than a new factory opening or a new medicine approval.
Cyprumed announced that MSD initiated a Phase 1 trial using its licensed oral tablet technology, triggering a milestone payment. The candidate and its structural class were undisclosed, so the program cannot be identified as a cyclic peptide. The earlier agreement’s potential $493 million comprises upfront and milestone payments, rather than cash already received. This is included as a delivery-platform reference.
NGK announced development of a ceramic-membrane device for lipid nanoparticle manufacturing. The concept adjusts membrane area and porosity to retain a common mixing principle across processing scales, addressing quality changes that can occur when manufacturers switch mixing technologies. NGK reported encouraging evaluation results, but the device remains under development; commercial-scale GMP validation was not established in the announcement.
Alex Chen’s long-form report compares salt selection, solid-state evidence, formulations and oral absorption for enlicitide and icotrokinra. Start with a short overview, then explore the full bilingual report through its chapter directory, comparison tables and original references.
ARPA-H selected five teams for its GIVE research program, with funding of up to $125 million for automated, distributed RNA medicine manufacturing. Selected approaches include RNA synthesis, lipid nanoparticle formulation, fill-finish, and integrated quality control. The agency plans engagement with FDA on regulatory frameworks. These are development objectives for technologies still being built, rather than established distributed GMP production capabilities.
Evonik announced a Vancouver expansion for GMP manufacturing of lipid-based drug products, involving more than C$150 million in investment and up to C$68 million in Canadian government support. The project includes production, quality control, and microbiology capabilities. Evonik expects the expansion to more than triple existing capacity; this is planned capacity rather than production already available to customers.
Quantoom Biosciences and Inside Therapeutics announced a nonexclusive commercial collaboration connecting Ntensify Micro and Mini RNA production with TAMARA lipid nanoparticle formulation. Activities include customer referrals, coordinated marketing, and shared events, while both businesses continue operating and selling independently. The agreement concerns research workflows and commercial coordination, rather than demonstrating a jointly validated, end-to-end GMP manufacturing process.
The study examined API crystals directly in Allegra, Clarith, and Ibrance tablets using selected-area 3D ED/MicroED. Fexofenadine hydrochloride Form I and clarithromycin Form II retained their polymorphs, while palbociclib Form A showed slight lattice shrinkage. The results demonstrate formulation-level structural analysis and emphasize that a lattice change and a new polymorph are different findings.
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.